key: cord-0983174-dp5ft4sr
authors: Burger, Achim Leo; Kaufmann, Christoph C.; Jäger, Bernhard; Pogran, Edita; Ahmed, Amro; Wojta, Johann; Farhan, Serdar; Huber, Kurt
title: Direct cardiovascular complications and indirect collateral damage during the COVID-19 pandemic: A review
date: 2021-10-20
journal: Wien Klin Wochenschr
DOI: 10.1007/s00508-021-01956-2
sha: 015d91509ed6f686ccefe81b1b25a4941a7ffaba
doc_id: 983174
cord_uid: dp5ft4sr

The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), puts a heavy strain on healthcare systems around the globe with high numbers of infected patients. Pre-existing cardiovascular disease is a major risk factor for a severe clinical course of COVID-19 and is associated with adverse outcome. COVID-19 may directly exacerbate underlying heart disease and is frequently aggravated by cardiovascular complications, including arterial and venous thromboembolic events, malignant arrhythmia and myocardial injury. In addition to these direct cardiac manifestations of COVID-19, patients with cardiovascular disease face further indirect consequences of the pandemic, as the respective resources in the healthcare systems need to be redirected to cope with the high numbers of infected patients. Consecutively, a substantial decrease in cardiac procedures was reported during the pandemic with lower numbers of coronary angiographies and device implantations worldwide. As a consequence an increased number of out-of-hospital cardiac arrests, late-comers with subacute myocardial infarction and of patients presenting in cardiogenic shock or preshock were observed. Maintenance of high-quality cardiac care by avoiding a reduction of cardiac services is of utmost importance, especially in times of a pandemic.

The coronavirus disease 2019 (COVID-19) caused a global pandemic with more than 140 million patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in more than 200 countries worldwide [1] . Patients with a history of cardiovascular disease represent a particularly vulnerable group with a high risk of a severe clinical course of the disease [2, 3] . Virus-related cardiovascular complications, such as myocardial injury, cardiac arrhythmia and thromboembolic events are a frequent finding in patients with COVID-19 [4] [5] [6] . In addition, treatment of cardiac patients is further hampered by a significant reduction in diagnostic and therapeutic strategies during the peaks of the pandemic [7] [8] [9] . Regarding the substantial impact on cardiovascular medicine, this review focuses on national and international experience with cardiac complications in COVID-19 patients and pandemic-related collateral damage. Table 1 Direct cardiovascular complications and respective incidence rates associated with COVID-19

Incidence rate of cardiovascular complications (%) Arterial thrombotic events 0.9-1.1 [28, 29] Venous thrombotic events 6-30 [4, [37] [38] [39] Myocardial inflammation 30-60 [50, 51] Cardiac arrhythmia 1-17 [54, 56] teins of the virus form a typical crown-like morphology with spike proteins on its surface [11] . The virus enters the host cells via binding of the spike proteins to the ACE-2 (Angiotensin-converting enzyme 2) receptor, a membrane protein with a particularly high expression on the surface of alveolar epithelial type II cells in the human respiratory tract, causing the typical respiratory symptoms [12, 13] . In the early phase of the pandemic, concerns about the safety of treatment with ACE inhibitors in COVID-19 patients were raised due an upregulation of the ACE-2 receptor [14] ; however, several studies and randomized control trials demonstrated that ACE inhibitors can be safely continued despite a SARS-CoV-2 infection [15] [16] [17] [18] .

The clinical course of COVID-19 varies significantly with many patients experiencing no or only mild symptoms, including fever, fatigue, dry cough and gastrointestinal symptoms [13, 19] . Nevertheless, a substantial number of COVID-19 patients are affected by a more severe clinical course with viral pneumonia and acute respiratory distress syndrome [19] . Notably, infection with SARS-CoV-2 often triggers an amplified inflammatory response with excessive cytokine release, platelet hyperactivity, endothelial dysfunction and systemic inflammation [20] [21] [22] [23] . This hyperinflammatory response may provide a potential explanation for the high incidence rate of cardiovascular complications in patients with COVID-19 (Table 1 ; Fig. 1 ; [20] ).

In addition, SARS-CoV-2 shows a propensity to genetic variations, leading to new variants that might differ in clinical presentation and characteristics [24] . In contrast to the previous year of the pandemic, the latest wave of infections in Europe is mainly driven by the emergence of the B.1.617.2 variant of the SARS-CoV-2 virus, also referred to as delta variant [24] . Data from the European Center for Disease Prevention and Control show that B.1.617.2 accounted for more than 65% of all cases across Europe in the calendar week 28 of July 2021 [24] . The delta variant is associated with a higher transmissibility and might influence the effectiveness of vaccination [25] .

The rapid emergence of new variants with a potentially higher risk for an aggravated course underlines the dynamic nature of the pandemic.

Thromboembolic events are a frequent complication in COVID-19 patients and contribute to increased morbidity and mortality [20] . Several studies demonstrated the high incidence of thromboembolism that affects both the arterial and the venous system [4, 26, 27] . A multinational observational cohort study of more than 14,000 patients reported that 1.1% of COVID-19 patients presented with acute ischemic stroke during initial hospital admission [28] . Similarly, a stroke rate of 0.9% was reported in a cohort study from New York [29] and COVID-19 was demonstrated to be an independent risk factor for the occurrence of ischemic stroke, with a significantly higher risk in patients with a severe clinical course [30, 31] . Of note, patients with COVID-19 appear to have an increased risk for cryptogenic and large vessel stroke [29, 32] . Patients presenting with ST elevation myocardial infarction (STEMI) and concurrent COVID-19 infection face an increased risk for a poor outcome [33, 34] . Several studies reported that STEMI patients with a concomitant SARS-CoV-2 infection carry a higher thrombus burden and an increased risk of stent thrombosis [33, 34] ; however, it remains controversial if SARS-CoV2 can trigger type 1 myocardial infarction itself, potentially via cytokine-related plaque instability [35, 36] .

Venous thrombotic events and pulmonary embolism frequently occur in patients with COVID-19 [37] [38] [39] . In a Dutch cohort of 184 critically ill patients, the incidence of venous thrombotic complications was 27% despite routine thromboprophylaxis with low molecular-weight heparin (LMWH) [4] . A French multicenter cohort study demonstrated an incidence rate of pulmonary embolism of 8.3% in 1240 consecutive COVID-19 patients, as confirmed with computed tomography pulmonary angiography [40] . As evidence of the activated coagulation system, several studies reported elevated plasma levels of D-dimer in a significant proportion of COVID-19 patients, associated with an adverse outcome [41, 42] . The high rates of thrombotic events make effective antithrombotic treatment essential in the management of COVID-19 patients. Hence, routine thromboprophylaxis with standard-dose LMWH should be established in all hospitalized patients [5, [43] [44] [45] . Selected high-risk patients may benefit from an intensified strategy with intermediate-dose or therapeutic-dose administration of LMWH [5, 43] , although the evidence for such dosage is still limited [46] .

Acute myocarditis related to COVID-19 was reported by several case series and smaller studies [47, 48] . In an initial observational study from Wuhan, China, fulminant myocarditis was suspected as the immediate cause of death in 7% of all patients [49] . A prospective Direct cardiovascular complications and indirect collateral damage during the COVID-19 pandemic K review article trial performed elective cardiac magnetic resonance imaging in 100 recently recovered COVID-19 patients and reported that 60 patients showed elevated T1 and T2 times, suggestive of myocardial inflammation with late gadolinium enhancement detected in 32 patients [50] . Endomyocardial biopsy was performed in patients with severe findings and showed diffuse active lymphocytic inflammation [50] . Similar findings were reported in a retrospective cohort study of patients with previous SARS-CoV-2 infection who underwent cardiac magnetic resonance imaging, demonstrating that 31% of these patients had significant late gadolinium enhancement [51] . A prospective multicenter study in a cohort of 148 patients with a severe clinical course of COVID-19 detected myocarditis-like scars in 39 (26%) patients via cardiac magnetic resonance imaging [52] . On the contrary, Joy et al. investigated cardiovascular changes in a cohort of 74 patients with a mild clinical course of COVID-19 compared with 75 seronegative control patients 6 months after infection [53] . Thorough analysis of cardiovascular biomarkers and cardiac magnetic resonance imaging did not reveal any long-term cardiovascular abnormalities in COVID-19 patients with only mild symptoms [53] .

This data might indicate that SARS-CoV-2 infection frequently causes extensive myocardial inflammation, which may be dependent on disease severity. Potential long-term cardiac sequelae of COVID-19 in this respect still need to be investigated.

Cardiac rhythm disorders are frequently reported in COVID-19 patients with higher incidence rates among patients with elevated troponin levels or patients on an intensive care unit [54, 55] . Guo et al. reported in a retrospective cohort study that patients with elevated troponin T levels had a significantly higher incidence rate of ventricular arrhythmia compared to patients with normal troponin levels (17.3% vs. 1.5%, p < 0.001) [54] . Data from an American registry of consecutive COVID-19 cases reported an incidence rate of malignant ventricular arrhythmia of 11% in patients with a severe clinical course [56] . A meta-analysis of 17 observational cohort studies found an incidence rate of 10.4% of cardiac arrhythmia in COVID-19 patients, although the type of arrhythmia was not clearly defined in this analysis [57] . The propensity for the occurrence of potentially life-threatening ventricular arrhythmia may be the consequence of several contributing factors. In addition to myocardial injury, COVID-19 patients frequently develop metabolic disorders and electrolyte disorders on top of the hyperinflammatory state, creating a milieu that may favor the occurrence of cardiac arrhythmia [56, 58] . It has to be stressed that several drugs initially used to treat COVID-19 have proarrhythmic potential, e.g. hydroxychloroquine and azithromcycin [59, 60] . Although it might pose a logistic challenge in routine clinical practice, selected inpatients might benefit from continuous rhythm monitoring.

In the COVID-19 era, governments worldwide were repeatedly forced to impose drastic public health measures to control and reduce transmission rates of SARS-CoV-2. Strict social distancing rules, selfisolation, quarantine, economic and social stress, in addition to fear of virus infection, exerted significant psychosocial distress on broad parts of the population [61, 62] . Emotional and physical distress are common triggers of the takotsubo syndrome, referred to as stress cardiomyopathy [63] . During the COVID-19 pandemic, a significant increase in the incidence rate of takotsubo syndrome was found [64] . Jabri et al. reported in a North American cohort that the incidence rate of takotsubo syndrome was 4.5 times higher during the COVID-19 pandemic compared to corresponding time frames of prepandemic years [65] . Interestingly, the vast majority of patients presenting with takotsubo syndrome in this study tested negative for SARS-CoV-2, potentially associated with an increased level of stress in the general population [65] .

Several studies demonstrated that patients with a history of cardiovascular comorbidities have a higher risk for an aggravated clinical course of COVID-19 [41, 42, 54, 66] .

In addition to the described direct cardiovascular complications induced by a COVID-19, the pandemic might have several indirect consequences due to a pandemic-related reduction in diagnostic and therapeutic strategies for patients with cardiovascular disease ([67]; Fig. 1 ). National healthcare systems in several countries had to relocate resources to cope with the high numbers of infected patients [68, 69] . Consequently, a substantial decrease in elective cardiac procedures was observed during the peaks of the COVID-19 pandemic, with significantly lower numbers of patients undergoing routine coronary angiography, pacemaker implantation or cardiac surgery ([9, 70, 71]; Fig. 1 ). Importantly, the numbers of acute procedures showed a comparable decline [7, [72] [73] [74] . An Italian study from 15 cardiac centers reported a reduction of 30% in patients admitted with acute coronary syndrome in February and March 2020, compared to the previous year's respective period [7] . Data from a French registry of 21 participating centers showed a reduction of 24% in hospital admissions for STEMI during the first lockdown, irrespective of the regional prevalence of COVID-19 [72] . Similar numbers were reported in studies from the USA and England [8, 73, 75, 76] . Recent data from Austria have shown that the Fig. 1 Direct cardiovascular complications of COVID-19 and indirect collateral damage during the pandemic. ACS acute coronary syndrome, ICD implantable cardioverter defibrillator, PM pacemaker, PCI percutaneous coronary intervention numbers of interventional cardiac procedures were significantly lower in the whole year of 2020 compared to the previous 12 months of 2019 [77] . While a significant reduction of 8% in elective percutaneous coronary interventions (PCI) was observed, the rate of acute PCI showed an even greater decline of 12% [77] . The number of cardiac device implantations and cardiac surgeries were also significantly affected by the pandemic-related lockdown measures [70, 78] . A nationwide analysis from England reported a substantial decline of 44% in pacemaker implantation and of 45% in implantable cardioverter defibrillator implantations during the first wave of the pandemic [78] . Patients admitted for coronary artery bypass craft surgery were markedly reduced by 64% and for surgical aortic valve replacement by 41% compared with the respective period in 2019 [78] . Similar numbers were reported from an Italian multicenter analysis and an international quantitative survey of 60 cardiac surgery centers [70, 79] .

Reduced capacities for cardiac patients and interventional procedures may have led to significant collateral damage (Fig. 1 ). An Italian multicenter study reported a threefold increase in STEMI case fatality rate (risk ratio, RR = 3.3, p < 0.001) and a substantial increase in complications (RR = 1.8, p = 0.009) during the COVID-19 pandemic [80] . These complications included cardiac rupture, ventricular septal defect and severe mitral regurgitation, which may be attributed to prolonged patient delay due to neglected symp-toms [80] . Accordingly, the delay from symptom onset to wire-crossing was substantially increased by 39.2% compared to the previous year's respective period [80] . In addition, a profound impact on out-of-hospital cardiac arrest was observed [81] . In the region of Lombardy, Italy, a 58% point increase in out-of-hospital cardiac arrests during the first peak of the pandemic compared to the same period of the previous year was noted [82] . Bystander cardiopulmonary resuscitation was performed significantly less often [82] . Likewise, an analysis from the Paris metropolitan area reported a transient two-times increased incidence rate of outof-hospital cardiac arrest in the period from March to April 2020 [83] . Furthermore, several studies found a significant decline in admission rates for patients with acute heart failure during the peaks of the pandemic [84, 85] . Patients presenting with worsening or new onset heart failure were in aggravated clinical conditions and had more severe symptoms [84] . Data from England and Germany suggested an increased mortality in heart failure patients during the pandemic [86, 87] , although these findings were not confirmed in a recent study from Denmark [88] . Importantly, a potential undertreatment of patients with heart failure during the pandemic may influence longterm prognosis of these patients [89] . Overall, an increased cardiovascular mortality in the COVID-19 era was observed in several studies. Wu et al. reported in a national cohort analysis of England and Wales a proportional increase in cardiovascular mortality of 8% compared with the average of the previous years [90] . An excess in cardiovascular death was also found in studies from the USA and Brazil [91, 92] ; how-Direct cardiovascular complications and indirect collateral damage during the COVID-19 pandemic K review article ever, a recent analysis from Danish nationwide registries did not identify an increased mortality of patients with established cardiovascular diseases during the pandemic [93] . In this context, it needs to be acknowledged that although increasing evidence for a profound pandemic-related impact on cardiovascular care is available, these data were mostly generated from observational studies [94] . Jung et al. demonstrated in a systematic evaluation that COVID-19 clinical research has lower methodological quality than comparable control studies and should be interpreted with appropriate care [94] .

The substantial decrease in hospital admissions and interventional cardiac procedures may have several causes. During the peaks of the pandemic, strict social distancing rules were imposed, avoidance of personal contact was encouraged and the risks of COVID-19 were broadly propagated through public media and the political discourse. Potentially, many patients opted to avoid hospitals and emergency services out of fear of contagion. Even patients with acute medical conditions, including typical signs of an ACS may try to endure symptoms for as long as possible before seeking adequate medical attention [95] . Such changes in patients' behavior led to a significant increase in patient delay and time to wirecrossing in STEMI patients [80, 95] . In addition, relocation of resources to deal with the high number of infected patients may have contributed to the declined numbers of cardiac procedures during the COVID-19 pandemic. Under the continuous pressure of the pandemic, healthcare providers were obliged to establish specialized COVID-19 wards on normal care and intensive care units. Resources from wards of cardiology departments were not excluded from such relocations, as the limited resources of bed capacities and medical staff were partly redirected from the treatment of cardiac patients to the high numbers of COVID-19 patients. As a consequence of these relocations, elective, non-emergency cardiac procedures had to be postponed during the peaks of the pandemic, which led to significantly lower numbers of interventional procedures [70, 71, 77] .

Regarding the significant impact of the pandemic on cardiovascular treatment, countermeasures should be considered [96, 97] . Maintenance of well-functioning cardiac care and specialized tertiary hospitals is of utmost importance, especially in times of a global pandemic. Considering the importance of timely primary PCI in the setting of STEMI, patients need to be adequately educated and encouraged to immediately seek medical attention if symptoms suggestive of an ACS are present [98, 99] . It should be emphasized that patients may not avoid contacting emergency services due to fear of potential nosocomial SARS-CoV-2 infections but rather focus on the importance of timely treatment in cases of an acute coronary event. In this context, maintenance of a wellfunctioning STEMI network is of great importance. Guideline-compliant, timely interventional treatment of patients with a STEMI or high-risk NSTEMI and continued appropriate treatment on specialized cardiac units should not be compromised despite shortages in personnel or resources. Thus, relocation of resources towards the appropriate care of COVID-19 patients may exclude cardiac departments, which carry the responsibility of continued cardiovascular treatment of a population at risk. Finally, it is of utmost need for governments and healthcare systems to provide public information and reassurance to the people to seek medical attention in case of acute or emergency conditions.

The COVID-19 pandemic poses a severe and persistent challenge to national healthcare systems. Patients with pre-existing heart diseases are a vulnerable patient group that may face both direct and indirect consequences of the COVID-19 pandemic. Cardiovascular complications occur frequently and aggravate the clinical course of the disease. While the high numbers of infected patients repeatedly forced healthcare systems to relocate the limited resources towards an adequate treatment of COVID-19 patients, appropriate high-quality care for patients with cardiovascular disease needs to be maintained to avoid collateral damage to this patient group.

Johns Hopkins Coronavirus Resource Center

Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic

Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Anticoagulation in COVID-19: a systematic review, meta-analysis, and rapid guidance from mayo clinic

COVID-19 -Kardiologische Aspekte

Reduced rate of hospital admissions for ACS during Covid-19 outbreak in northern Italy

Reduction in ST-segment elevation cardiac catheterization laboratory activations in the United States during COVID-19 pandemic

Decrease in cardiac catheterization and MI during COVID pandemic

A new coronavirus associated with human respiratory disease in China

Origin and evolution of pathogenic coronaviruses

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Pharmacologic modulation of ACE2 expression

Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: a randomized clinical trial

Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial

Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial

Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19

Chinese Center for Disease Control and Prevention. The epidemiologicalcharacteristicsofanoutbreakof2019novel coronavirus diseases (COVID-19) in China

Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation

Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19

Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19

Hypercoagulability of COVID-19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis

Weekly surveillance summary

Effectiveness of Covid-19 vaccines against the B.1.617.2 (delta) variant

Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in

Ischemic stroke in COVID-19-positive patients: an overview of SARS-CoV-2 and thrombotic mechanisms for the neurointerventionalist

Cerebrovascular events and outcomes in hospitalized patients with COVID-19: the SVIN COVID-19 multinational registry

SARS-coV-2 and stroke in a New York healthcare system

COVID-19 is an independent risk factor for acute Ischemic stroke

Neurologic manifestations of hospitalized patients with coronavirus disease

Large-vessel stroke as a presenting feature of Covid-19 in the young

High thrombus burden in patients with COVID-19 presenting with ST-segment elevation myocardial infarction

Characteristics and outcomes in patients presenting with COVID-19 and ST-segment elevation myocardial infarction

Association of coronary plaque rupture and atherosclerotic inflammation

Influenza infection exerts prominent inflammatory and thrombotic effects on the atherosclerotic plaques of apolipoprotein E-deficient mice

Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia

Thrombosis in hospitalized patients with COVID-19 in a New York City health system

Registry of arterial and venous thromboembolic complications in patients with COVID

Pulmonary embolism in COVID-19 patients: a French multicentre cohort study

Clinical characteristics of coronavirus disease 2019 in China

Clinicalcourseand risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

AktualisierteEmpfehlungen zur Thromboseprophylaxe bei SARS-CoV-2 (COVID-19)

COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and followup: JACC state-of-the-art review

Scientific and standardization committee communication: clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19

Recent randomized trials of antithrombotic therapy for patients with COVID-19: JACC state-of-the-art review

COVID-19-related myocarditis in a 21-year-old female patient

Systematic review of COVID-19 related myocarditis: insights on management and outcome

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19)

Cardiac involvement in patients recovered from COVID-2019 identified using magnetic resonance imaging

Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance

Prospective case-control study of cardiovascular abnormalities 6 months following mild COVID-19 in healthcare workers

Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)

Death, discharge and arrhythmias among patients with COVID-19 and cardiac injury

Malignant arrhythmias in patients with COVID-19: incidence, mechanisms, and outcomes. Circ Arrhythm Electrophysiol

Cardiovascular complications in COVID-19: a systematic review and meta-analysis

Assessment of hypokalemia and clinical characteristics in patients with coronavirus disease

QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin

QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: a systematic review and meta-analysis

COVID-19pandemicandmental health consequences: systematic review of the current evidence

The psychological impact of quarantine and how to reduce it: rapid review of the evidence

International expert consensus document on Takotsubo syndrome (part I): clinical characteristics, diagnostic criteria, and pathophysiology

Incidence of stress cardiomyopathy during the coronavirus disease 2019 pandemic

Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019

Verlauf undTherapie kardiovaskulärer Erkrankungen im Rahmen der Covid-19-Pandemie

COVID-19 experience in Bergamo, Italy

The impact of COVID-19 on the provision of cardiac surgical services

Impact of COVID-19 pandemic on the clinical activities related to arrhythmias and electrophysiology in Italy: results of a survey promoted by AIAC (Italian association of arrhythmology and cardiac pacing)

The impact of the COVID-19 pandemic on cardiac surgery and transplant services in Ireland's national centre

Hospital admissions for acute myocardial infarction before and after lockdown according to regional prevalence of COVID-19 and patient profile in France: a registry study

Decline of acute coronary syndrome admissions in Austria since the outbreak of COVID-19: the pandemic response causes cardiac collateral damage

Complications and mortality of cardiovascular emergency admissions during COVID-19 associated restrictive measures

Effect of the COVID-19 pandemic on treatment delays in patients with ST-segment elevation myocardial infarction

COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England

Herzkathetereingriffsdaten im COVID-Pandemiejahr 2020 im Vergleich zu 2019 aus dem österreichischen ANCALAR-Register

Cardiac operations and interventions during the COVID-19 pandemic: a nationwide perspective

Response of cardiac surgery units to COVID-19: an internationally-based quantitative survey. Circulation

Reductionofhospitalizationsformyocardial infarction in Italy in the COVID-19 era

Cardiac arrest in the COVID-19 era

Out-of-hospital cardiac arrest during the Covid-19 outbreak in Italy

Out-of-hospital cardiac arrest during the COVID-19 pandemic

The impact of COVID-19 on heart failure hospitalization and management: report from a heart failure unit in London during the peak of the pandemic

Impact of COVID-19 on inpatient referral of acute heart failure: a single-centre experience from the south-west of the UK. ESC Heart Fail

Temporal trends in decompensated heart failure and outcomes during COVID-19: a multisite report from heart failure referral centres in London

In-hospital mortality in heart failure in Germany during the Covid-19 pandemic

Incidence of new-onset and worsening heart failure before and after the COVID-19 epidemic lockdown in Denmark: a nationwide cohort study

The next wave of health care strain related to COVID-19: heart

Place and causes of acute cardiovascular mortality during the COVID-19 pandemic

Fewer hospitalizations for acute cardiovascular conditions during the COVID-19 pandemic

Excess of cardiovascular deaths during the COVID-19 pandemic in Brazilian capital cities

All-cause mortality and location of death in patients with established cardiovascular disease before, during, and after the COVID-19 lockdown: a Danish nationwide cohort study

Methodological quality of COVID-19 clinical research

Increased mortality and worse cardiac outcome of acute myocardial infarction during the early COVID-19 pandemic

Covid-19: implications for prehospital, emergency and hospital care in patients with acute coronary syndromes

EAPCI position statement on invasive management of acute coronary syndromes during the COVID-19 pandemic

Impact of treatment delay on mortality in ST-segment elevation myocardial infarction (STEMI) patients presenting with and without haemodynamic instability: results from the German prospective, multicentre FITT-STEMI trial

ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European society of cardiology (ESC)